TYPHIM-VI VACCINE - TOLERANCE AND IMMUNOGENICITY 2 STUDIES ON HEALTHY PATIENTS

The efficacy of Typhim Vi, an inactivated polyosidic vaccine, was assessed by studies performed in endemic areas (South Africa - Nepal). We realized two studies, in order to evaluate tolerance and immunogenicity of this vaccine. The first one (n = 83) was to evaluate Typhim Vi administered alone, the second one (n = 72) to evaluate the combination of Typhim Vi and T. Polio. This combination was performed either in two different inoculation sites (left and right arm) either previously realized in the same syringe. These two studies demonstrated the excellent tolerance of Typhim Vi, either alone or combined with T. Polio. A significative rise in antibodies was demonstrated in 97% of cases in the first study, and in 100 % in the second one.